Nxera Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Nxera Pharma hat ein Gesamteigenkapital von ¥67.8B und eine Gesamtverschuldung von ¥64.9B, was einen Verschuldungsgrad von 95.8% ergibt. Die Gesamtaktiva und Gesamtpassiva betragen ¥152.3B bzw. ¥84.6B.

Wichtige Informationen

95.8%

Verhältnis von Schulden zu Eigenkapital

JP¥64.90b

Verschuldung

Zinsdeckungsgrad	n/a
Bargeld	JP¥48.87b
Eigenkapital	JP¥67.76b
Gesamtverbindlichkeiten	JP¥84.58b
Gesamtvermögen	JP¥152.34b

Jüngste Berichte zur Finanzlage

Is Nxera Pharma (TSE:4565) A Risky Investment?

Apr 06

Recent updates

Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Sep 25

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Jun 26

Is Nxera Pharma (TSE:4565) A Risky Investment?

Apr 06

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Mar 08

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: 4565Die kurzfristigen Aktiva des Unternehmens (¥59.9B) übersteigen seine kurzfristigen Passiva (¥14.9B).

Langfristige Verbindlichkeiten: 4565Die kurzfristigen Vermögenswerte des Unternehmens (¥59.9B) decken seine langfristigen Verbindlichkeiten (¥69.6B) nicht.

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: 4565Die Nettoverschuldung im Verhältnis zum Eigenkapital (23.7%) wird als zufriedenstellend angesehen.

Schulden abbauen: 4565Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 4% auf 95.8% gestiegen.

Bilanz

Liquiditätsreserve-Analyse

Bei Unternehmen, die in der Vergangenheit im Durchschnitt Verluste gemacht haben, wird geprüft, ob sie über einen Liquiditätsvorlauf von mindestens einem Jahr verfügen.

Stabile Start- und Landebahn für Bargeld: Obwohl 4565 unrentabel ist, verfügt es über eine ausreichende Cash-Runway für mehr als 3 Jahre, wenn es seinen derzeitigen positiven freier Cashflow beibehält.

Vorhersage Cash Runway: 4565 ist unrentabel, verfügt aber über eine ausreichende Liquiditätsreserve für mehr als drei Jahre, da der freie Cashflow positiv ist und um 12.7% pro Jahr wächst.

Nxera Pharma Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Is Nxera Pharma (TSE:4565) A Risky Investment?

Recent updates

New minor risk - Share price stability

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nxera Pharma Co., Ltd. Appoints Makoto Sugita as President of Nxera Pharma Japan, and Executive Officer, Executive Vice President and Chief Medical Officer of Nxera Pharma

Nxera Pharma Co., Ltd. (TSE:4565) Stocks Pounded By 25% But Not Lagging Industry On Growth Or Pricing

Nxera Pharma Co., Ltd. to Report Q3, 2024 Results on Nov 01, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Nxera Pharma Co., Ltd.'s (TSE:4565) P/S Still Appears To Be Reasonable

Nxera Pharma Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568

Is Nxera Pharma (TSE:4565) A Risky Investment?

Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC

Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease

Sosei Group Corporation (TSE:4565) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable

Sosei Group Corporation to Report Q1, 2024 Results on May 09, 2024

Now 24% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sosei Group Corporation, Annual General Meeting, Mar 27, 2024

Now 21% overvalued after recent price rise

Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer

New minor risk - Shareholder dilution

Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea

Sosei Group Corporation to Report Fiscal Year 2023 Results on Feb 13, 2024

New minor risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Idorsia Pharmaceuticals Japan Ltd. Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for the Approval of Daridorexant

Price target decreased by 9.0% to JP¥2,281

Consensus revenue estimates increase by 12%

Sosei Group Corporation to Report Q3, 2023 Results on Nov 10, 2023

Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732

Second quarter 2023 earnings released: JP¥8.01 loss per share (vs JP¥17.95 loss in 2Q 2022)

Price target increased by 8.2% to JP¥2,443

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia

Now 38% undervalued after recent price drop

Consensus EPS estimates fall by 30%

New major risk - Share price stability

Price target decreased by 16% to JP¥2,957

Sosei Group Corporation to Report Q2, 2023 Results on Aug 04, 2023

Price target increased by 8.9% to JP¥3,500

Now 21% undervalued

Consensus EPS estimates increase by 30%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 39%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Sosei Group Corporation, Annual General Meeting, Mar 23, 2023

Sosei Group Corporation to Report Fiscal Year 2022 Results on Feb 14, 2023

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Third quarter 2022 earnings released: EPS: JP¥3.82 (vs JP¥5.80 in 3Q 2021)

Sosei Group Corporation to Report Q3, 2022 Results on Nov 11, 2022

Price target increased to JP¥2,950

Second quarter 2022 earnings released: JP¥17.95 loss per share (vs JP¥14.11 loss in 2Q 2021)

Sosei Heptares' Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development Under Multi-Program Collaboration with Neurocrine Biosciences

Consensus revenue estimates increase by 18%

Cancer Research UK and Sosei Heptares Signs Agreement to Advance Cancer Immunotherapy Candidate into Clinical Trials

Sosei Group Corporation to Report Q2, 2022 Results on Aug 10, 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 15%

Price target decreased to JP¥2,600

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Sosei Group Corporation, Annual General Meeting, Mar 24, 2022

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

Consensus revenue estimates increase to JP¥16.5b

Price target increased to JP¥2,767

Third quarter 2021 earnings released: EPS JP¥5.80 (vs JP¥5.94 in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: JP¥14.11 loss per share (vs JP¥17.76 loss in 2Q 2020)

High number of new directors

Sosei Heptares Initiates Phase 1 Trial With Novel Small-Molecule CGRP Antagonist Under Collaboration With Biohaven

Sosei Group Corporation Provides Update of Their Strategic Multi-Target Drug Discovery Collaboration with Pfizer

First quarter 2021 earnings released: JP¥14.28 loss per share (vs JP¥9.68 loss in 1Q 2020)

Full year 2020 earnings released: EPS JP¥18.78 (vs JP¥18.69 in FY 2019)